|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen P, Liu Y, Wen Y and Zhou C: Non-small
cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
|
4
|
Xue J, Li B, Wang Y, Huang Z, Liu X, Guo
C, Zheng Z, Liang N, Le X and Li S: Efficacy and safety of
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor
combination therapy as first-line treatment for patients with
advanced EGFR-mutated, non-small cell lung cancer: A systematic
review and bayesian network meta-analysis. Cancers (Basel).
14:48942022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li D, Ambrogio L, Shimamura T, Kubo S,
Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A,
Himmelsbach F, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor
highly effective in preclinical lung cancer models. Oncogene.
27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chhouri H, Alexandre D and Grumolato L:
Mechanisms of acquired resistance and tolerance to EGFR targeted
therapy in non-small cell lung cancer. Cancers (Basel). 15:5042023.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mu Y, Hao X, Xing P, Hu X, Wang Y, Li T,
Zhang J, Xu Z and Li J: Acquired resistance to osimertinib in
patients with non-small-cell lung cancer: mechanisms and clinical
outcomes. J Cancer Res Clin Oncol. 146:2427–2433. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang JCH, Camidge DR, Yang CT, Zhou J, Guo
R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, et al: Safety,
efficacy, and pharmacokinetics of almonertinib (HS-10296) in
pretreated patients with EGFR-mutated advanced NSCLC: A
multicenter, open-label, phase 1 trial. J Thorac Oncol.
15:1907–1918. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hwang JK, Page BJ, Flynn D, Passmore L,
McCaul E, Brady J, Yang IA, Marshall H, Windsor M, Bowman RV, et
al: Validation of the eighth edition TNM lung cancer staging
system. J Thorac Oncol. 15:649–654. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shu Y, Wu X, Tong X, Wang X, Chang Z, Mao
Y, Chen X, Sun J, Wang Z, Hong Z, et al: Circulating tumor DNA
mutation profiling by targeted next generation sequencing provides
guidance for personalized treatments in multiple cancer types. Sci
Rep. 7:5832017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hockenhull K, Ortega-Franco A and Califano
R: Pembrolizumab plus platinum-based chemotherapy for squamous
non-small cell lung cancer: The new kid on the block. Transl Lung
Cancer Res. 10:3850–3854. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu
X, Bao H, Tong X, Wang X, Shao YW, et al: Investigating novel
resistance mechanisms to third-generation EGFR tyrosine kinase
inhibitor osimertinib in non-small cell lung cancer patients. Clin
Cancer Res. 24:3097–3107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bolger AM, Lohse M and Usadel B:
Trimmomatic: A flexible trimmer for Illumina sequence data.
Bioinformatics. 30:2114–2120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Newman AM, Bratman SV, Stehr H, Lee LJ,
Liu CL, Diehn M and Alizadeh AA: FACTERA: A practical method for
the discovery of genomic rearrangements at breakpoint resolution.
Bioinformatics. 30:3390–3393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koboldt DC, Zhang Q, Larson DE, Shen D,
McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK:
VarScan 2: Somatic mutation and copy number alteration discovery in
cancer by exome sequencing. Genome Res. 22:568–576. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F
and Ou SI: Beyond osimertinib: The development of third-generation
EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac
Oncol. 16:740–763. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian M, Lu Z, Chen S, Lu G, Bu F, Deng W
and Ding R: 1014P Resistance landscape to almonertinib in
EGFR-mutated NSCLC. Ann Oncol. 33 (Suppl 7):S10172022. View Article : Google Scholar
|
|
18
|
Kwon Y, Kim M, Jung HS, Kim Y and Jeoung
D: Targeting autophagy for overcoming resistance to anti-EGFR
treatments. Cancers (Basel). 11:13742019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bersanelli M, Minari R, Bordi P, Gnetti L,
Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G,
Capelletto E, et al: L718Q Mutation as new mechanism of acquired
resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol.
11:e121–e123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leonetti A, Sharma S, Minari R, Perego P,
Giovannetti E and Tiseo M: Resistance mechanisms to osimertinib in
EGFR-mutated non-small cell lung cancer. Br J Cancer. 121:725–737.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu
VW, Albacker L, Stephens PJ, Miller VA and Ali SM: Emergence of
novel and dominant acquired EGFR solvent-front mutations at Gly796
(G796S/R) together with C797S/R and L792F/H mutations in one EGFR
(L858R/T790M) NSCLC patient who progressed on osimertinib. Lung
Cancer. 108:228–231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin L, Lu Q, Cao R, Ou Q, Ma Y, Bao H, Wu
X, Shao Y, Wang Z and Shen B: Acquired rare recurrent EGFR
mutations as mechanisms of resistance to Osimertinib in lung cancer
and in silico structural modelling. Am J Cancer Res. 10:4005–4015.
2020.PubMed/NCBI
|
|
23
|
Ricciuti B, Baglivo S, De Giglio A and
Chiari R: Afatinib in the first-line treatment of patients with
non-small cell lung cancer: Clinical evidence and experience. Ther
Adv Respir Dis. 12:17534666188086592018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Kempen LC, Wang H, Aguirre ML, Spatz
A, Kasymjanova G, Vilacha JF, Groves MR, Agulnik J and Small D:
Afatinib in osimertinib-resistant EGFR ex19del/T790M/P794L mutated
NSCLC. J Thorac Oncol. 13:e161–e163. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang W, Huang Y, Gan J, Zheng Q and Zhang
L: Emergence of EGFR G724S after progression on osimertinib
responded to afatinib monotherapy. J Thorac Oncol. 15:e36–e37.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Jin B, Su H, Qu X and Liu Y:
Afatinib helped overcome subsequent resistance to osimertinib in a
patient with NSCLC having leptomeningeal metastasis baring acquired
EGFR L718Q mutation: A case report. BMC Cancer. 19:7022019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang W, Gan J, Huang Y, Zhou H and Zhang
L: Acquired EGFR L718V mutation and loss of T790M-mediated
resistance to osimertinib in a patient with NSCLC who responded to
afatinib. J Thorac Oncol. 14:e274–e275. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang X, Huang C, Chen R and Zhao J:
Resolving resistance to osimertinib therapy with afatinib in an
NSCLC patient with EGFR L718Q mutation. Clin Lung Cancer.
21:e258–e260. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Minari R, Leonetti A, Gnetti L, Zielli T,
Ventura L, Bottarelli L, Lagrasta C, La Monica S, Petronini PG,
Alfieri R and Tiseo M: Afatinib therapy in case of EGFR G724S
emergence as resistance mechanism to osimertinib. Anticancer Drugs.
32:758–762. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao Y, Chen Y, Huang H, Li X, Shao L and
Ding H: Significant benefits of afatinib and apatinib in a
refractory advanced NSCLC patient resistant to osimertinib: A case
report. Onco Targets Ther. 14:3063–3067. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang G, Yan B, Guo Y, Yang H, Li X and Li
J: Case report: A patient with the rare third-generation
TKI-resistant mutation EGFR L718Q who responded to afatinib plus
cetuximab combination therapy. Front Oncol. 12:9956242022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song Z, Ren G, Wang X, Du H, Sun Y and Hu
L: Durable clinical benefit from afatinib in a lung adenocarcinoma
patient with acquired EGFR L718V mutation-mediated resistance
towards osimertinib: A case report and literature review. Ann
Palliat Med. 11:1126–1134. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nozaki K, Watanabe S, Nishio K, Sakai K
and Kikuchi T: Effectiveness of afatinib in an NSCLC patient with
EGFR mutation and early progression to osimertinib: a case report.
Transl Cancer Res. 11:295–298. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aredo JV, Wakelee HA, Neal JW and Padda
SK: Afatinib after progression on osimertinib in EGFR-mutated
non-small cell lung cancer. Cancer Treat Res Commun. 30:1004972022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sanchis-Borja M, Guisier F, Swalduz A,
Curcio H, Basse V, Maritaz C, Chouaid C and Auliac JB:
Characterization of patients with EGFR mutation-positive NSCLC
following emergence of the osimertinib resistance mutations, L718Q
or G724S: A multicenter retrospective observational study in
France. Onco Targets Ther. 17:439–448. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karachaliou N, Fernandez-Bruno M, Bracht
JWP and Rosell R: EGFR first- and second-generation TKIs-there is
still place for them in EGFR-mutant NSCLC patients. Transl Cancer
Res. 8 (Suppl 1):S23–S47. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang JCH, Schuler M, Popat S, Miura S,
Heeke S, Park K, Märten A and Kim ES: Afatinib for the treatment of
NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J
Thorac Oncol. 15:803–815. 2020. View Article : Google Scholar : PubMed/NCBI
|
